Off-Label Pacira Warning Letter Dropped From FDA's Website
This article was originally published in The Gray Sheet
FDA has apparently taken down a warning letter from its website describing off-label marketing violations by Pacira Pharmaceuticals, a drug company that is suing the agency over First Amendment free speech rights. The agency’s response in the lawsuit is due this month.
You may also be interested in...
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.